Cerebral Palsy Treatment Market by Drug Type (Anticholinergics, Anticonvulsants, Antidepressants, and Others), Disease Type (Spastic Cerebral Palsy Treatment, Dyskinetic Cerebral Palsy Treatment, Ataxic Cerebral Palsy Treatment, and Mixed Cerebral Palsy Treatment), Distribution Channel (Hospital pharmacies, Retail Stores & Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2021–2030
The global cerebral palsy treatment market was valued at $3166.82 million in 2020, and is projected to reach $4,365.01 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.
Cerebral palsy is a group of disorders that affect a person’s ability to move and maintain balance and posture. Cerebral palsy is the most common motor disability in childhood. Cerebral palsy is caused by abnormal brain development or damage to the developing brain that affects a person’s ability to control his or her muscles.
Patients suffering from cerebral palsy require lifelong care with a medical care team. Although there is no cure for cerebral palsy there are various treatments like medications, therapies, surgical procedures and other treatments. Medications include muscle or nerve injections, and oral muscle relaxants. Major therapies include physical therapies, occupational therapies, speech and language therapies and recreational therapies.
The factors that drive the growth of the global cerebral palsy treatment market include upsurge in the prevalence of cerebral palsy, rising focus on the healthcare technological advancements coupled with growing availability of newer cerebral palsy drugs, increasing research and development proficiencies, government initiatives to promote the awareness and increasing reliance on medications are the major factors prevailing the growth of the global cerebral palsy treatment market.
However, high costs associated with medications is expected to create hindrances for the growth of the cerebral palsy treatment market. Moreover, Side effects associated with the medications such as drowsiness, depression, headaches, lethargy, confusion, and dizziness and lack of awareness in the backward and underdeveloped economies are causing hurdles in the cerebral palsy treatment market.
Various initiatives have been taken by the government to encourage the regulatory affairs in getting approvals for novel drugs, and insurance policies which are creating lucrative opportunities in the cerebral palsy treatment market.
The report segments the market based on drug type, disease type, distribution channel, and region. Based on drug type, it is classified into anticholinergics, anticonvulsants, antidepressants, and others. Based on disease type, it is classified into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy. Based on distribution channel, the market is divided into hospital pharmacies, retail stores and pharmacies, and online providers. Based on the region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Region wise, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the cerebral palsy treatment market in 2020, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to significant rise in investments as well as partnerships and collaborations.
Business expansions is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global cerebral palsy treatment market. The key companies profiled in the report include Merz Pharmaceuticals, LLC., Pfizer Inc., Teva Pharmaceuticals, Bayer AG, Johnson & Johnson, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, Allergan plc., Lannett Company, Inc.
KEY BENEFITS FOR STAKEHOLDERS
The report provides in-depth analysis of the global Cerebral Palsy Treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Cerebral Palsy Treatment market growth.
KEY MARKET SEGMENTS
By Drug Type
Anticholinergics
Anticonvulsants
Antidepressants
Other
By Disease Type
Spastic Cerebral Palsy
Dyskinetic Cerebral Palsy
Ataxic Cerebral Palsy
Mixed Cerebral Palsy
By Distribution Channel
Hospital Pharmacies
Retail stores and Pharmacy
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report:
Merz Pharmaceuticals, LLC.
Pfizer Inc.
Teva Pharmaceuticals
Bayer AG
Johnson & Johnson
GlaxoSmithKline plc.
Novartis
AbbVie Inc.
Par Pharmaceutical.
Allergan plc
Lannett Company, Inc.
- Chapter 1:Introduction
- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
- 1.4.Research methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- Chapter 2:Executive summary
- 2.1.Key findings of the study
- 2.2.CXO perspective
- Chapter 3:MARKET LANDSCAPE
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.2.2.Top winning strategies
- 3.3.Porter’s five force analysis
- 3.4.Top player positioning, 2020
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.1.1.Increase in incidences of cerebral palsy
- 3.5.1.2.Rise in investments by key player
- 3.5.2.Restraint
- 3.5.2.1.Side effects associated with drugs
- 3.5.3.Opportunity
- 3.5.3.1.Initiatives by governments for regulatory approvals
- 3.6.COVID-19 impact analysis on cerebral palsy treatment market
- Chapter 4:cerebral palsy treatment market, by drug type
- 4.1.Overview
- 4.1.1.Market size and forecast
- 4.2.Anticholinergics
- 4.2.1.Market size and forecast, by region
- 4.2.2.Market analysis, by country
- 4.3.Anticonvulsants
- 4.3.1.Market size and forecast, by region
- 4.3.2.Market analysis, by country
- 4.4.Antidepressants
- 4.4.1.Market size and forecast, by region
- 4.4.2.Market analysis, by country
- 4.5.Others
- 4.5.1.Market size and forecast, by region
- 4.5.2.Market analysis, by country
- Chapter 5:cerebral palsy treatment market, by Disease type
- 5.1.Overview
- 5.1.1.Market size and forecast
- 5.2.Spastic Cerebral Palsy
- 5.2.1.Market size and forecast, by region
- 5.2.2.Market analysis, by country
- 5.3.Dyskinetic Cerebral Palsy
- 5.3.1.Market size and forecast, by region
- 5.3.2.Market analysis, by country
- 5.4.Ataxic Cerebral Palsy
- 5.4.1.Market size and forecast, by region
- 5.4.2.Market analysis, by country
- 5.5.Mixed Cerebral Palsy
- 5.5.1.Market size and forecast, by region
- 5.5.2.Market analysis, by country
- Chapter 6:cerebral palsy treatment market, by Distribution Channel
- 6.1.Overview
- 6.1.1.Market size and forecast
- 6.2.Hospital Pharmacy
- 6.2.1.Market size and forecast, by region
- 6.2.2.Market analysis, by country
- 6.3.Retail store and pharmacy
- 6.3.1.Market size and forecast, by region
- 6.3.2.Market analysis, by country
- 6.4.Online providers
- 6.4.1.Market size and forecast, by region
- 6.4.2.Market analysis, by country
- Chapter 7:Cerebral Palsy Treatment market, by region
- 7.1.Overview
- 7.1.1.Market size and forecast
- 7.2.North America
- 7.2.1.Key market trends, growth factors, and opportunities
- 7.2.2.Market size and forecast, by country
- 7.2.2.1.U.S.
- 7.2.2.1.1.U.S. Cerebral Palsy Treatment market, by drug type
- 7.2.2.1.2.U.S. Cerebral Palsy Treatment market, by disease type
- 7.2.2.1.3.U.S. Cerebral Palsy Treatment market, by distribution channel
- 7.2.2.2.Canada
- 7.2.2.2.1.Canada Cerebral Palsy Treatment market, by drug type
- 7.2.2.2.2.Canada Cerebral Palsy Treatment market, by disease type
- 7.2.2.2.3.Canada Cerebral Palsy Treatment market, by distribution channel
- 7.2.2.3.Mexico
- 7.2.2.3.1.Mexico Cerebral Palsy Treatment market, by drug type
- 7.2.2.3.2.Mexico Cerebral Palsy Treatment market, by disease type
- 7.2.2.3.3.Mexico Cerebral Palsy Treatment market, by distribution channel
- 7.2.3.North America market size and forecast, by drug type
- 7.2.4.North America market size and forecast, by disease type
- 7.2.5.North America market size and forecast, by distribution channel
- 7.3.Europe
- 7.3.1.Key market trends, growth factors, and opportunities
- 7.3.2.Market size and forecast, by country
- 7.3.2.1.Germany
- 7.3.2.1.1.Germany Cerebral Palsy Treatment market, by drug type
- 7.3.2.1.2.Germany Cerebral Palsy Treatment market, by disease type
- 7.3.2.1.3.Germany Cerebral Palsy Treatment market, by distribution channel
- 7.3.2.2.France
- 7.3.2.2.1.France Cerebral Palsy Treatment market, by drug type
- 7.3.2.2.2.France Cerebral Palsy Treatment market, by disease type
- 7.3.2.2.3.France Cerebral Palsy Treatment market, by distribution channel
- 7.3.2.3.UK
- 7.3.2.3.1.UK Cerebral Palsy Treatment market, by drug type
- 7.3.2.3.2.UK Cerebral Palsy Treatment market, by disease type
- 7.3.2.3.3.UK Cerebral Palsy Treatment market, by distribution channel
- 7.3.2.4.Italy
- 7.3.2.4.1.Italy Cerebral Palsy Treatment market, by drug type
- 7.3.2.4.2.Italy Cerebral Palsy Treatment market, by disease type
- 7.3.2.4.3.Italy Cerebral Palsy Treatment market, by distribution channel
- 7.3.2.5.Spain
- 7.3.2.5.1.Spain Cerebral Palsy Treatment market, by drug type
- 7.3.2.5.2.Spain Cerebral Palsy Treatment market, by disease type
- 7.3.2.5.3.Spain Cerebral Palsy Treatment market, by distribution channel
- 7.3.2.6.Rest of Europe
- 7.3.2.6.1.Rest of Europe Cerebral Palsy Treatment market, by drug type
- 7.3.2.6.2.Rest of Europe Cerebral Palsy Treatment market, by disease type
- 7.3.2.6.3.Rest of Europe Cerebral Palsy Treatment market, by distribution channel
- 7.3.3.Europe market size and forecast, by drug type
- 7.3.4.Europe market size and forecast, by disease type
- 7.3.5.Europe market size and forecast, by distribution channel
- 7.4.Asia-Pacific
- 7.4.1.Key market trends, growth factors, and opportunities
- 7.4.2.Market size and forecast, by country
- 7.4.2.1.Japan
- 7.4.2.1.1.Japan Cerebral Palsy Treatment market, by drug type
- 7.4.2.1.2.Japan Cerebral Palsy Treatment market, by disease type
- 7.4.2.1.3.Japan Cerebral Palsy Treatment market, by distribution channel
- 7.4.2.2.China
- 7.4.2.2.1.China Cerebral Palsy Treatment market, by drug type
- 7.4.2.2.2.China Cerebral Palsy Treatment market, by disease type
- 7.4.2.2.3.China Cerebral Palsy Treatment market, by distribution channel
- 7.4.2.3.Australia
- 7.4.2.3.1.Australia Cerebral Palsy Treatment market, by drug type
- 7.4.2.3.2.Australia Cerebral Palsy Treatment market, by disease type
- 7.4.2.3.3.Australia Cerebral Palsy Treatment market, by distribution channel
- 7.4.2.4.India
- 7.4.2.4.1.India Cerebral Palsy Treatment market, by drug type
- 7.4.2.4.2.India Cerebral Palsy Treatment market, by disease type
- 7.4.2.4.3.India Cerebral Palsy Treatment market, by distribution channel
- 7.4.2.5.South Korea
- 7.4.2.5.1.South Korea Cerebral Palsy Treatment market, by drug type
- 7.4.2.5.2.South Korea Cerebral Palsy Treatment market, by disease type
- 7.4.2.5.3.South Korea Cerebral Palsy Treatment market, by distribution channel
- 7.4.2.6.Rest of Asia-Pacific
- 7.4.2.6.1.Rest of Asia-Pacific Cerebral Palsy Treatment market, by drug type
- 7.4.2.6.2.Rest of Asia-Pacific Cerebral Palsy Treatment market, by disease type
- 7.4.2.6.3.Rest of Asia-Pacific Cerebral Palsy Treatment market, by distribution channel
- 7.4.3.Asia-Pacific market size and forecast, by drug type
- 7.4.4.Asia-Pacific market size and forecast, by disease type
- 7.4.5.Asia-Pacific market size and forecast, by distribution channel
- 7.5.LAMEA
- 7.5.1.Key market trends, growth factors, and opportunities
- 7.5.2.Market size and forecast, by country
- 7.5.2.1.Brazil
- 7.5.2.1.1.Brazil Cerebral Palsy Treatment market, by drug type
- 7.5.2.1.2.Brazil Cerebral Palsy Treatment market, by disease type
- 7.5.2.1.3.Brazil Cerebral Palsy Treatment market, by distribution channel
- 7.5.2.2.Saudi Arabia
- 7.5.2.2.1.Saudi Arabia Cerebral Palsy Treatment market, by drug type
- 7.5.2.2.2.Saudi Arabia Cerebral Palsy Treatment market, by disease type
- 7.5.2.2.3.Saudi Arabia Cerebral Palsy Treatment market, by distribution channel
- 7.5.2.3.South Africa
- 7.5.2.3.1.South Africa Cerebral Palsy Treatment market, by drug type
- 7.5.2.3.2.South Africa Cerebral Palsy Treatment market, by disease type
- 7.5.2.3.3.South Africa Cerebral Palsy Treatment market, by distribution channel
- 7.5.2.4.Rest of LAMEA
- 7.5.2.4.1.Rest of LAMEA Cerebral Palsy Treatment market, by drug type
- 7.5.2.4.2.Rest of LAMEA Cerebral Palsy Treatment market, by disease type
- 7.5.2.4.3.Rest of LAMEA Cerebral Palsy Treatment market, by distribution channel
- 7.5.3.LAMEA market size and forecast, by drug type
- 7.5.4.LAMEA market size and forecast, by disease type
- 7.5.5.LAMEA market size and forecast, by distribution channel
- Chapter 8:Company profiles
- 8.1.ABBVIE INC.
- 8.1.1.Company overview
- 8.1.2.Company snapshot
- 8.1.3.Operating business segments
- 8.1.4.Product portfolio
- 8.1.5.Business performance
- 8.1.6.Key strategic moves and developments
- 8.2.BAYER AG
- 8.2.1.Company overview
- 8.2.2.Company snapshot
- 8.2.3.Operating business segments
- 8.2.4.Product portfolio
- 8.2.5.Business performance
- 8.3.GLAXOSMITHKLINE PLC.
- 8.3.1.Company overview
- 8.3.2.Company snapshot
- 8.3.3.Operating business segments
- 8.3.4.Product portfolio
- 8.3.5.Business performance
- 8.4.JOHNSON AND JOHNSON
- 8.4.1.Company overview
- 8.4.2.Company snapshot
- 8.4.3.Operating business segments
- 8.4.4.Product portfolio
- 8.4.5.Business performance
- 8.4.6.Key strategic moves and developments
- 8.5.LANNETT COMPANY, INC.
- 8.5.1.Company overview
- 8.5.2.Company snapshot
- 8.5.3.Operating business segments
- 8.5.4.Product portfolio
- 8.5.5.Business performance
- 8.5.6.Key strategic moves and developments
- 8.6.MERZ PHARMACEUTICALS, LLC.
- 8.6.1.Company overview
- 8.6.2.Company snapshot
- 8.6.3.Operating business segments
- 8.6.4.Product portfolio
- 8.6.5.Key strategic moves and developments
- 8.7.NOVARTIS
- 8.7.1.Company overview
- 8.7.2.Company snapshot
- 8.7.3.Operating business segments
- 8.7.4.Product portfolio
- 8.7.5.Business performance
- 8.8.PAR PHARMACEUTICALS
- 8.8.1.Company overview
- 8.8.2.Company snapshot
- 8.8.3.Operating business segments
- 8.8.4.Product portfolio
- 8.9.PFIZER, INC.
- 8.9.1.Company overview
- 8.9.2.Company snapshot
- 8.9.3.Operating business segments
- 8.9.4.Product portfolio
- 8.9.5.Business performance
- 8.10.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.
- 8.10.1.Company overview
- 8.10.2.Company snapshot
- 8.10.3.Operating business segments
- 8.10.4.Product portfolio
- 8.10.5.Business performance
- LIST OF TABLES
- TABLE 01.CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 02.CEREBRAL PALSY TREATMENT MARKET FOR ANTICHOLINERGIC, BY REGION, 2020–2030 ($MILLION)
- TABLE 03.CEREBRAL PALSY TREATMENT MARKET FOR ANTICONVULSANTS, BY REGION, 2020–2030 ($MILLION)
- TABLE 04.CEREBRAL PALSY TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2020–2030 ($MILLION)
- TABLE 05.CEREBRAL PALSY TREATMENT MARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
- TABLE 06.CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 07.CEREBRAL PALSY TREATMENT MARKET FOR SPASTIC CEREBRAL PALSY, BY REGION, 2020–2030 ($MILLION)
- TABLE 08.CEREBRAL PALSY TREATMENT MARKET FOR DYSKINETIC CEREBRAL PALSY, BY REGION, 2020–2030 ($MILLION)
- TABLE 09.CEREBRAL PALSY TREATMENT MARKET FOR ATAXIC CEREBRAL PALSY, BY REGION, 2020–2030 ($MILLION)
- TABLE 10.CEREBRAL PALSY TREATMENT MARKET FOR MIXED CEREBRAL PALSY, BY REGION, 2020–2030 ($MILLION)
- TABLE 11.CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 12.CEREBRAL PALSY TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
- TABLE 13.CEREBRAL PALSY TREATMENT MARKET FOR RETAIL STORES AND PHARMACY, BY REGION, 2020–2030 ($MILLION)
- TABLE 14.CEREBRAL PALSY TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2020–2030 ($MILLION)
- TABLE 15.CEREBRAL PALSY TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
- TABLE 16.NORTH AMERICA CEREBRAL PALSY TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
- TABLE 17.U.S. CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 18.U.S. CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 19.U.S. CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 20.CANADA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 21.CANADA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 22.CANADA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 23.MEXICO CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 24.MEXICO CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 25.MEXICO CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 26.NORTH AMERICA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 27.NORTH AMERICA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 28.NORTH AMERICA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 29.EUROPE CEREBRAL PALSY TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
- TABLE 30.GERMANY CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 31.GERMANY CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 32.GERMANY CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 33.FRANCE CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 34.FRANCE CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 35.FRANCE CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 36.UK CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 37.UK CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 38.UK CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 39.ITALY CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 40.ITALY CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 41.ITALY CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 42.SPAIN CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 43.SPAIN CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 44.SPAIN CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 45.REST OF EUROPE CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 46.REST OF EUROPE CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 47.REST OF EUROPE CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 48.EUROPE CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 49.EUROPE CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 50.EUROPE CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 51.ASIA-PACIFIC CEREBRAL PALSY TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
- TABLE 52.JAPAN CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 53.JAPAN CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 54.JAPAN CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 55.CHINA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 56.CHINA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 57.CHINA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 58.AUSTRALIA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 59.AUSTRALIA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 60.AUSTRALIA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 61.INDIA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 62.INDIA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 63.INDIA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 64.SOUTH KOREA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 65.SOUTH KOREA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 66.SOUTH KOREA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 67.REST OF ASIA-PACIFIC CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 68.REST OF ASIA-PACIFIC CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 69.REST OF ASIA-PACIFIC CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 70.ASIA-PACIFIC CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 71.ASIA-PACIFIC CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 72.ASIA-PACIFIC CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 73.LAMEA CEREBRAL PALSY TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
- TABLE 74.BRAZIL CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 75.BRAZIL CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 76.BRAZIL CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 77.SAUDI ARABIA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 78.SAUDI ARABIA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 79.SAUDI ARABIA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 80.SOUTH AFRICA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 81.SOUTH AFRICA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 82.SOUTH AFRICA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 83.REST OF LAMEA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 84.REST OF LAMEA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 85.REST OF LAMEA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 86.LAMEA CEREBRAL PALSY TREATMENT MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
- TABLE 87.LAMEA CEREBRAL PALSY TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
- TABLE 88.LAMEA CEREBRAL PALSY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
- TABLE 89.ABBVIE INC: COMPANY SNAPSHOT
- TABLE 90.ABBVIE INC.: OPERATING SEGMENTS
- TABLE 91.ABBVIE INC: PRODUCT PORTFOLIO
- TABLE 92.ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 93.BAYER AG: COMPANY SNAPSHOT
- TABLE 94.BAYER AG: OPERATING SEGMENTS
- TABLE 95.BAYER AG: PRODUCT PORTFOLIO
- TABLE 96.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 97.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
- TABLE 98.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 99.J&J: COMPANY SNAPSHOT
- TABLE 100.J&J: OPERATING BUSINESS SEGMENTS
- TABLE 101.J&J: PRODUCT PORTFOLIO
- TABLE 102.J & J: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 103.LANNETT COMPANY, INC..: COMPANY SNAPSHOT
- TABLE 104.LANNETT COMPANY, INC..: OPERATING SEGMENTS
- TABLE 105.LANNETT COMPANY, INC.: PRODUCT PORTFOLIO
- TABLE 106.LANNETT COMPANY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 107.MERZ PHARMACEUTICALS, LLC.: COMPANY SNAPSHOT
- TABLE 108.MERZ PHARMACEUTICALS, LLC...: OPERATING SEGMENTS
- TABLE 109.MERZ PHARMACEUTICALS, LLC..: PRODUCT PORTFOLIO
- TABLE 110.MERZ PHARMACEUTICALS, LLC..: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 111.NOVARTIS: COMPANY SNAPSHOT
- TABLE 112.NOVARTIS: OPERATING SEGMENTS
- TABLE 113.NOVARTIS: PRODUCT PORTFOLIO
- TABLE 114.PAR PHARMACEUTICALS.: COMPANY SNAPSHOT
- TABLE 115.PAR PHARMACEUTICALS.: OPERATING SEGMENTS
- TABLE 116.PAR PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 117.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 118.PFIZER: OPERATING SEGMENTS
- TABLE 119.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 120.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: COMPANY SNAPSHOT
- TABLE 121.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: OPERATING SEGMENTS
- TABLE 122.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01.CEREBRAL PALSY TREATMENT MARKET SEGMENTATION
- FIGURE 02.TOP INVESTMENT POCKETS, 2020
- FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021*
- FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2021*
- FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019–2021*
- FIGURE 06.LOW-TO-MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 07.HIGH BARGAINING POWER OF BUYERS
- FIGURE 08.MODERATE THREAT OF SUBSTITUTES
- FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
- FIGURE 10.HIGH INTENSITY OF COMPETITIVE RIVALRY
- FIGURE 11.TOP PLAYER POSITIONING, 2020
- FIGURE 12.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR ANTICHOLINERGIC, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 13.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR ANTICONVULSANTS, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 14.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR ANTIDEPRESSANTS, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 15.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 16.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR SPASTIC CEREBRAL PALSY, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 17.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR DYSKINETIC CEREBRAL PALSY, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 18.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR ATAXIC CEREBRAL PALSY, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 19.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR MIXED CEREBRAL PALSY, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 20.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 21.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 22.COMPARATIVE ANALYSIS OF CEREBRAL PALSY TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 23.ABBVIE INC: NET SALES, 2018–2020 ($ MILLION)
- FIGURE 24.ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 25.ABBVIE INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 26.BAYER: NET SALES, 2018–2020 ($ MILLION)
- FIGURE 27.BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
- FIGURE 28.BAYER: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 29.GLAXOSMITHKLINE PLC.: NET SALES, 2018–2020 ($ MILLION)
- FIGURE 30.GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 31.GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 32.J&J: NET SALES, 2018–2020 ($ MILLION)
- FIGURE 33.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
- FIGURE 34.J&J: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 35.LANNETT COMPANY, INC.: NET SALES, 2018–2020 ($ MILLION)
- FIGURE 36.LANNETT COMPANY, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 37.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
- FIGURE 38.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 39.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 40.PFIZER INC.: NET SALES, 2018–2020 ($ MILLION)
- FIGURE 41.PFIZER INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
- FIGURE 42.PFIZER INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 43.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2018–2020 ($ MILLION)
- FIGURE 44.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook